Cardiac Resynchronization Therapy Vegetations.

Heart Views

Non-Invasive Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Published: February 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144418PMC
http://dx.doi.org/10.4103/heartviews.heartviews_124_22DOI Listing

Publication Analysis

Top Keywords

cardiac resynchronization
4
resynchronization therapy
4
therapy vegetations
4
cardiac
1
therapy
1
vegetations
1

Similar Publications

Background: Transvenous cardiac implantable electronic device (CIED) lead extraction (TLE) is susceptible to superior vena cava (SVC) injury and can be performed in the operating room (OR) or electrophysiology lab via a mechanical device or laser-powered extraction. This study reflects a contemporary experience of mechanical right-left rotational extraction by cardiac surgeons in the OR.

Methods: We conducted a retrospective single-center review of adult (age ≥18 years) TLE cases performed by cardiac surgeons between 2019 and 2021.

View Article and Find Full Text PDF

Cardiac resynchronization therapy (CRT) reduces heart failure (HF) hospitalizations and all-cause mortality in patients with HF with reduced ejection fraction with left bundle branch (LBB) block. Biventricular pacing (BVP) is considered the gold standard for achieving CRT; however, approximately 30%-40% of patients do not respond to BVP-CRT. Recent studies have demonstrated that LBB pacing (LBBP) produces remarkable results in CRT.

View Article and Find Full Text PDF

Background: Cardiac resynchronization therapy (CRT) response relies on 2 factors: when and where to pace. These factors may be enhanced by dynamic atrioventricular delays (AVDs) (eg, SyncAV CRT, Abbott Cardiovascular, Abbott Park, IL) and multisite left ventricular (LV) pacing (eg, MultiPoint Pacing [MPP], Abbott). Their individual and combined synchronization contributions have not been evaluated across a comprehensive spectrum of pacing configurations.

View Article and Find Full Text PDF

2-Year Follow-Up of Baroreflex Activation Therapy for Severe Heart Failure With Reduced Ejection Fraction.

JACC Case Rep

March 2025

Department of Cardiology, Santa Marta Hospital, Unidade Local de Saúde São José, Lisbon, Portugal; Faculty of Medicine of Lisbon, Cardiovascular Centre of the University of Lisbon, Lisbon, Portugal.

Background: Baroreflex activation therapy (BAT) is a novel treatment for heart failure with reduced ejection fraction (HFrEF) in patients who remain symptomatic despite optimal medical therapy (OMT) and who are unsuitable for cardiac resynchronization therapy (CRT). BAT modulates the autonomic nervous system by electrically stimulating carotid baroreceptors, thus potentially improving heart function and symptoms.

Cases Summary: Two male HFrEF patients with nonischemic cardiomyopathy, symptomatic (NYHA functional class III) despite OMT, underwent successful BAT implantation.

View Article and Find Full Text PDF

Introduction: Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real- world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!